



GRN Frontotemporal Dementia

Synonym: FTD-GRN

Ging-Yuek Robin Hsiung, MD, MHS¹, FRCPC¹ and Howard H Feldman, MD, CM, FRCPC²

Created: September 7, 2007; Updated: February 6, 2020.

Summary

Clinical characteristics

The spectrum of *GRN* frontotemporal dementia (*GRN*-FTD) includes the behavioral variant (bvFTD), primary progressive aphasia (PPA; further subcategorized as progressive nonfluent aphasia [PNFA] and semantic dementia [SD]), and movement disorders with extrapyramidal features such as parkinsonism and corticobasal syndrome (CBS). A broad range of clinical features both within and between families is observed. The age of onset ranges from 35 to 87 years. Behavioral disturbances are the most common early feature, followed by progressive aphasia. Impairment in executive function manifests as loss of judgment and insight. In early stages, PPA often manifests as deficits in naming, word finding, or word comprehension. In late stages, affected individuals often become mute and lose their ability to communicate. Early findings of parkinsonism include rigidity, bradykinesia or akinesia (slowing or absence of movements), limb dystonia, apraxia (loss of ability to carry out learned purposeful movements), and disequilibrium. Late motor findings may include myoclonus, dysarthria, and dysphagia. Most affected individuals eventually lose the ability to walk. Disease duration is three to 12 years.

Diagnosis/testing

The diagnosis of *GRN*-FTD is established in a proband with suggestive findings and a heterozygous pathogenic variant in *GRN* identified by molecular genetic testing.

Management

Treatment of manifestations: Behavioral manifestations such as apathy, impulsivity, and compulsiveness may respond to selective serotonin reuptake inhibitors. Roaming, delusions, and hallucinations may respond to antipsychotic medications. Reports have suggested potential benefits with certain pharmacotherapy on management of FTD; however, evidence from randomized controlled trials is limited. Small-scale studies have

Author Affiliations: 1 Associate Professor, Division of Neurology, Faculty of Medicine, University of British Columbia and Providence Health Care, Vancouver, British Columbia, Canada; Email: hsiung@mail.ubc.ca. 2 Professor, Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Email: howard.feldman@ubc.ca.

suggested that trazodone may be helpful for treating irritability, agitation, depression, and eating disorders; methylphenidate and dextro-amphetamine may help minimize risk-taking behavior. Cholinesterase inhibitors examined in clinical trials were generally well tolerated: galantamine was used to treat PPA with stabilization of symptoms; rivastigmine was used to treat behavioral manifestations and appeared to decrease caregiver burden. Two open-label studies of memantine, an NMDA partial agonist-antagonist, demonstrated some efficacy on frontal behavior in those with bvFTD and improvement in cognitive performance in those with PPA-PNFA.

Genetic counseling

GRN-FTD is inherited in an autosomal dominant manner. About 95% of individuals diagnosed with *GRN*-FTD have an affected parent. The proportion of affected individuals with a *de novo GRN* pathogenic variant is unknown but is estimated to be 5% or fewer. Each child of an individual with *GRN*-FTD has a 50% chance of inheriting the pathogenic variant. Once a *GRN* pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible.

Diagnosis

Suggestive Findings

GRN frontotemporal dementia (*GRN*-FTD) **should be suspected** in individuals with the following clinical presentations and neuroimaging findings.

Clinical Presentations

Clinical presentations of *GRN*-FTD vary widely both among and within families and may resemble behavioral variant FTD (bvFTD), primary progressive aphasia (PPA), atypical parkinsonism, or corticobasal syndrome.

Behavioral variant FTD [Rascovsky et al 2011]

- Early behavioral disinhibition (including one of the following):
 - Socially inappropriate behavior
 - Loss of manners or decorum
 - Impulsive, rash, or careless actions
- Early apathy or inertia (one of the following):
 - Apathy
 - Inertia
- Early loss of sympathy or empathy (one of the following):
 - Diminished response to other people's needs and feelings
 - Diminished social interest, interrelatedness, or personal warmth
- Early perseverative, stereotyped, or compulsive/ritualistic behavior (one of the following):
 - Simple repetitive movements
 - Complex, compulsive, or ritualistic behaviors
 - Stereotypy of speech
- Hyperorality and dietary changes (one of the following):
 - Altered food preferences
 - Binge eating, increased consumption of alcohol or cigarettes
 - Oral exploration or consumption of inedible objects
- Neuropsychological profile: executive/generation deficits with relative sparing of memory and visuospatial functions (**all** of the following):
 - Deficits in executive tasks
 - Relative sparing of episodic memory

- Relative sparing of visuospatial skills

Primary progressive aphasia (PPA). PPA has been further classified into three subtypes [Gorno-Tempini et al 2011]:

- Progressive nonfluent aphasia (PNFA, also known as nonfluent or agrammatic subtype of PPA)
- Semantic dementia (SD)
- Logopenic variant (logopenic PPA)

Note: To date, the logopenic variant has not been associated with *GRN*-FTD.

The majority of the literature describes PNFA to be the predominant form of PPA in *GRN*-FTD, although there are a few reports of the SD phenotype as well.

The currently proposed diagnostic algorithm for PNFA requires a two-step process. First, individuals must meet the criteria for PPA, and after the diagnosis of PPA is established, the main features of the speech and language abnormalities may be considered to subcategorize into each of the PPA variants.

The diagnostic criteria of PPA [Mesulam 2001]:

- The most prominent clinical feature is difficulty with language.
- Language deficits are the principal cause of impaired daily living activities.
- Aphasia is the most prominent deficit at symptom onset and for the initial phases of the disease.

Note: The pattern of deficits cannot be accounted for by other nondegenerative diseases of the nervous system, medical disorders, or psychiatric diagnoses.

PPA subtypes

- **Nonfluent variant of PPA (PPA-PNFA).** The diagnostic criteria of PPA-PNFA include clinical presentation of aphasia with [Gorno-Tempini et al 2011]:
 - At least one of the following core features:
 - Agrammatism in language production
 - Effortful, halting speech with inconsistent speech sound errors and distortions (apraxia of speech)
 - At least two of the three following supportive features:
 - Impaired comprehension of syntactically complex sentences
 - Spared single-word comprehension
 - Spared object knowledge
- **Semantic variant of PPA (PPA-SD).** The diagnostic criteria of PPA-SD require the presence of both of the following core features:
 - Impaired confrontation naming
 - Impaired single-word comprehension

AND at least three of the following four additional diagnostic features:

- Impaired object knowledge, particularly for low frequency or low-familiarity items
- Surface dyslexia or dysgraphia
- Spared repetition
- Spared speech production (grammar and motor speech)

Atypical parkinsonism. Clinical features include the following:

- Bradykinesia

- Rigidity
- Gait instability
- Resting tremor

Corticobasal syndrome. Clinical features include the following [Armstrong et al 2013]:

- Progressive asymmetric rigidity
- Apraxia
- Alien-limb phenomenon
- Cortical sensory loss
- Focal dystonia
- Myoclonus
- Dementia

Neuroimaging

Computed tomography (CT) or magnetic resonance imaging (MRI) may show focal, often asymmetric atrophy in the frontal, temporal, and/or parietal lobes [Rohrer & Warren 2011]. Volumetric studies comparing the rate of brain atrophy between *GRN*-FTD and *MAPT*-FTD showed that individuals with *GRN*-FTD have a higher rate of whole-brain atrophy (3.5% per year) than those with *MAPT*-related FTD [Whitwell et al 2011].

Single photon emission computed tomography (SPECT) may reveal decreased perfusion in the frontal and temporal lobes [Pasquier et al 2003]. There is also evidence of poor cerebral perfusion in both anterior parietal lobes, predominantly on the left hemisphere and on the right inferior parietal cortex [Le Ber et al 2008].

Positron emission tomography (PET) may demonstrate decreased glucose metabolism in the frontal and temporal regions in the presymptomatic stage prior to structural changes [Jacova et al 2013, Caroppo et al 2015].

Establishing the Diagnosis

The diagnosis of *GRN* frontotemporal dementia (*GRN*-FTD) **is established** in a proband with a heterozygous pathogenic (or likely pathogenic) variant in *GRN* by molecular genetic testing (see Table 1).

Note: (1) Per ACMG/AMP variant interpretation guidelines, the terms "pathogenic variants" and "likely pathogenic variants" are synonymous in a clinical setting, meaning that both are considered diagnostic and both can be used for clinical decision making [Richards et al 2015]. Reference to "pathogenic variants" in this section is understood to include any likely pathogenic variants. (2) Identification of a heterozygous *GRN* variant of uncertain significance does not establish or rule out the diagnosis.

Gene-targeted testing (multigene panel) requires that the clinician determine which gene(s) are likely involved, whereas comprehensive genomic testing does not. Because the phenotype of *GRN*-FTD is broad, individuals with the distinctive findings described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas those in whom the diagnosis of *GRN*-FTD has not been considered are more likely to be diagnosed using genomic testing (see Option 2).

Option 1

A frontotemporal dementia multigene panel that includes *GRN* and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this *GeneReview*. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the

clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests. For *GRN*-FTD a multigene panel that also includes deletion/duplication analysis is recommended (see Table 1).

For an introduction to multigene panels click [here](#). More detailed information for clinicians ordering genetic tests can be found [here](#).

Option 2

Comprehensive genomic testing. Exome sequencing is most commonly used; **genome sequencing** is also possible. If exome sequencing is not diagnostic – and particularly when evidence supports autosomal dominant inheritance – **exome array** (when clinically available) may be considered to detect (multi)exon deletions or duplications that cannot be detected by sequence analysis.

For an introduction to comprehensive genomic testing click [here](#). More detailed information for clinicians ordering genomic testing can be found [here](#).

Table 1. Molecular Genetic Testing Used in *GRN* Frontotemporal Dementia

Gene ¹	Method	Proportion of Probands with a Pathogenic Variant ² Detectable by Method
<i>GRN</i>	Sequence analysis ³	~98.5% ⁴
	Gene-targeted deletion/duplication analysis ⁵	~1.5% ^{4, 6}

1. See Table A. Genes and Databases for chromosome locus and protein.

2. See Molecular Genetics for information on allelic variants detected in this gene.

3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click [here](#).

4. Cruts et al [2006], Chen-Plotkin et al [2011], Van Langenhove et al [2013], Pottier et al [2018]. Note: Pottier et al [2018] identified 449 affected individuals with *GRN* disease-associated variants detected by sequence and deletion/duplication analysis in the ascertainment step of a genome-wide association study (see Pottier et al [2018], Supplementary Table 2).

5. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications. Gene-targeted deletion/duplication testing will detect deletions ranging from a single exon to the whole gene; however, breakpoints of large deletions and/or deletion of adjacent genes (e.g., those described by Milan et al [2017]) may not be detected by these methods.

6. Gijssels et al [2008], Pickering-Brown et al [2008], Rovelet-Lecrux et al [2008], Finch et al [2009], Chen-Plotkin et al [2011], Rohrer et al [2013], Van Langenhove et al [2013], Clot et al [2014]

Clinical Characteristics

Clinical Description

GRN frontotemporal dementia (*GRN*-FTD) generally affects the frontal and temporal cortex leading to behavioral changes, executive dysfunction, and language disturbances. In *GRN*-FTD, the parietal cortex and basal ganglia may be affected as well, resulting in parkinsonism, cortical basal syndrome, and memory impairment [Baker et al 2006, Masellis et al 2006, Mukherjee et al 2006, Behrens et al 2007, Josephs et al 2007, Mesulam et al 2007, Spina et al 2007].

Age of onset. The age of onset of *GRN*-FTD ranges from 35 to 87 years with a mean of 64.9 ± 11.3 years [Bruni et al 2007, Le Ber et al 2007, Rademakers et al 2007, Chen-Plotkin et al 2011].

Comparison studies demonstrate that onset age in individuals with *GRN*-FTD does not differ significantly from that in individuals without an identified *GRN* pathogenic variant [Beck et al 2008, Pickering-Brown et al 2008], while some studies suggested a younger onset age in those with *GRN*-FTD [Huey et al 2006, Davion et al 2007].

Neurocognitive symptoms. Neuropsychological testing may demonstrate early impairment on frontal lobe tasks or specific language dysfunction prior to the onset of frank dementia.

Behavioral disturbances are the most common early feature, followed by progressive aphasia [Gass et al 2006, Josephs et al 2007]. This is usually an insidious but profound change in personality and conduct, characterized by distractibility, loss of initiative, apathy, and loss of interest in their environment, often accompanied by neglect in personal hygiene and social disinhibition. Some affected individuals demonstrate impulsiveness or compulsiveness and may alter their eating habits with food fads and food craving.

With impairment in executive function, there is loss of judgment and insight, which may manifest early in the disease course as, for example, making poor financial decisions, quitting jobs abruptly, or becoming unduly forward or rude to strangers. Alternatively, persons with predominant apathy may lose all interest and initiative with usual activities, appear socially withdrawn, give up all previous hobbies and interests, and be unable to complete tasks due to lack of persistence. Early in the course of the illness, affected individuals may be misdiagnosed as having psychiatric conditions such as depression, mania, or psychosis because of the unusual and bizarre nature of their behavior. Psychometric testing may demonstrate impairment on frontal executive tasks including the Trail-Making Test, proverb interpretation, descriptions of similarities, categorical naming, and abstract pattern recognition (e.g., Wisconsin Card Sort Test).

Language deficits. Primary progressive aphasia (PPA), particularly the progressive nonfluent aphasia (PNFA) variant, can be another presentation of *GRN*-FTD [Mesulam et al 2007]. In early stages, PPA-PNFA often manifests as deficits in naming, word finding, or word comprehension. Although behavioral manifestations tend to be more common than language deficits as the initial presentation of *GRN*-FTD, in one series 82% of affected individuals eventually developed language issues [Josephs et al 2007, Caso et al 2012].

In contrast with PPA-PNFA, semantic dementia is characterized by impaired naming and comprehension, semantic paraphasias, and impaired recognition of familiar faces or objects. Although rare in *GRN*-FTD, pure semantic dementia (PPA-SD) has been described in a few studies [Whitwell et al 2007, Beck et al 2008]. In late stages, individuals with PPA-SD may develop impaired face recognition and behavioral changes including disinhibition and compulsion [Seeley et al 2005].

A number of studies have reported individuals with *GRN*-FTD who have presented with amnesic mild cognitive impairment, which may be mistaken for Alzheimer disease [Carecchio et al 2009, Kelley et al 2010].

Movement disorders. In several families with *GRN*-FTD, parkinsonism is prominent, and in some the initial clinical diagnosis was corticobasal syndrome [Gass et al 2006, Masellis et al 2006, Benussi et al 2009, Moreno et al 2009]. Early findings include rigidity, bradykinesia or akinesia (slowing or absence of movements), limb dystonia, apraxia (loss of ability to carry out learned purposeful movements), and disequilibrium. Late motor findings may include myoclonus, dysarthria, and dysphagia. Most affected individuals eventually lose the ability to walk.

Motor neuron disease. Although the histopathologic findings of ubiquitin-positive inclusions were initially associated with motor neuron disease, it appears to occur only rarely (if at all) in *GRN*-FTD [Schymick et al 2007].

Disease course. The mean age at death is 65±8 years. Disease duration ranges from three to 12 years [Gass et al 2006].

Neuropathology. The neuropathology of *GRN*-FTD is characterized by the following [Mackenzie et al 2006, Mackenzie et al 2011]:

- Tau-negative alpha-synuclein-negative ubiquitin-positive "cat-eye" or lentiform-shaped neuronal intranuclear inclusions (NII), often found in the neocortex and striatum
- Superficial laminar spongiosis with ubiquitin-positive neurites and neuronal cytoplasmic inclusions (NCI) in the neocortex
- Granular appearance of the ubiquitin-immunoreactive (ub-ir) neurites in the striatum and the NCI in the hippocampus
- Phosphorylation of S409/410 of TDP-43 in pathologic inclusions [Neumann et al 2009]

The major protein component of these ubiquitin inclusions is a TAR DNA-binding protein of 43 kd (TDP-43). TDP-43 is a nuclear factor involved in regulating transcription and alternative splicing [Arai et al 2006, Neumann et al 2006]. It is mostly a nuclear protein, although recent studies have shown that it shuttles between the nucleus and cytoplasm in normal conditions [Ayala et al 2008]. While its physiologic function remains unclear, it has been demonstrated to bind to a large number of RNA targets with a preference for UG-rich intronic regions and is important in many vital cellular processes [Sendtner 2011].

It is now recognized that pathologically, *GRN*-FTD is a major subtype of frontotemporal lobar degeneration (FTLD). The neuropathologic diagnostic criteria for FTLD have been updated based on current molecular understanding of the disease [Mackenzie et al 2011].

Genotype-Phenotype Correlations

No obvious correlations between age of onset, disease duration, or clinical phenotype and specific *GRN* pathogenic variants have been identified. Clinical variability is high among individuals with the same *GRN* pathogenic variant.

Penetrance

Penetrance of *GRN*-FTD is about 90% by age 75 years, but apparent reduced penetrance has also been observed on occasion [Cruts et al 2006, Gass et al 2006].

A study of the common p.Arg493Ter pathogenic variant showed that 60% of individuals with this variant were affected by age 60 years, and more than 95% were affected by age 70 years [Rademakers et al 2007]. Age at onset of frontotemporal lobar degeneration (FTLD) was younger in individuals with a *GRN* pathogenic variant vs those without one (median: 58.0 vs 61.0 years), as was age at death (median: 65.5 vs 69.0 years) [Chen-Plotkin et al 2011].

In a large series in France, 3.2% of simplex cases (i.e., only one affected individual in a family) with FTD were found to have a *GRN* pathogenic variant, suggesting possible *de novo* variant or incomplete penetrance [Le Ber et al 2007].

Nomenclature

The term frontotemporal dementia (FTD) is used in this *GeneReview* to designate the clinical presentation of the dementing illness, while the term frontotemporal lobar degeneration (FTLD) is used to denote the pathologic diagnosis of the disease.

Note that *PGRN*, the earlier designation for the gene *GRN*, may be used in the literature as well (e.g., *PGRN*-FTD).

Prior to the identification of *GRN* as the gene in which a pathogenic variant is responsible for this form of FTD, a number of terms were used to describe this disorder.

- **FTDU-17.** Analogous to FTDP-17, the term "FTDU-17" has been used because the pathologic characteristics of this condition are associated with **ubiquitinated** inclusions and the genetic locus was also located on chromosome 17.
- **HDDD1 and HDDD2.** Familial dementia in other kindreds with similar clinical presentations was descriptively named hereditary dysphasic disinhibition dementia (HDDD1 and HDDD2). It has now been shown that *GRN* pathogenic variants are also responsible for the phenotype in these families, and therefore these are now considered *GRN*-FTD [Mukherjee et al 2006, Behrens et al 2007].

Prevalence

Frontotemporal dementia (FTD) accounts for 5%-10% of all individuals with dementia and 10%-20% of individuals with dementia with onset before age 65 years [Bird et al 2003].

GRN-FTD represents about 5% of all FTD, and 20% of FTD in which the family history is positive.

Genetically Related (Allelic) Disorders

Individuals with biallelic *GRN* pathogenic variants and the phenotype of neuronal ceroid lipofuscinosis, a lysosomal storage disease that is strikingly different from FTD, have been reported [Smith et al 2012, Kamate et al 2019]. This finding further highlights the role of *GRN* in lysosomal function and regulation (see Molecular Genetics).

Differential Diagnosis

Neuroimaging can evaluate for other conditions that mimic frontotemporal dementia (FTD) (e.g., white matter diseases, frontotemporal focal lesions, frontal lobe tumors, and cerebrovascular disease).

The clinical manifestations of *GRN*-FTD significantly overlap with those of other conditions including FTD with or without parkinsonism associated with pathogenic variants in *MAPT*, [Parkinson disease](#), [Alzheimer disease](#), Pick disease (OMIM 172700), other inherited FTD disorders, corticobasal degeneration, progressive supranuclear palsy, and Creutzfeldt-Jacob disease (OMIM 123400). This clinical overlap makes it difficult to predict which family has a *GRN* pathogenic variant by clinical presentation alone.

Up to 50% of individuals with FTD have a positive family history of dementia, usually with autosomal dominant inheritance. Table 2 below lists the most common genes associated with familial FTD.

Table 2. Genes in the Differential Diagnosis of *GRN* Frontotemporal Dementia

Gene(s)	DiffDx Disorder	Clinical Features of DiffDx Disorder			
		Onset	Disease Duration	Pathology	Comment
Most commonly involved genes					
<i>C9orf72</i>	ALS & FTD	Mean: 54.3 yrs; range: 34-74 yrs	Mean: 5.3 yrs; range: 1-16 yrs	TDP-43 pathology is found in a wide neuroanatomic distribution, w/particular involvement in extramotor neocortex & hippocampus & in lower motor neurons	May be misdiagnosed as bvFTD, PPA-PNEA, or ALS. ¹ Heterogeneity in clinical presentation is common w/in families. Phenotypes tend to converge w/disease progression.

Table 2. continued from previous page.

Gene(s)	DiffDx Disorder	Clinical Features of DiffDx Disorder			
		Onset	Disease Duration	Pathology	Comment
<i>MAPT</i>	FTDP-17 (See MAPT-Related Frontotemporal Dementia .)	Usually age 40-60 yrs; may occur earlier or later	Usually 5-10 yrs; may be up to 20-30 yrs	At autopsy, all persons w/ FTDP-17 show tau-positive inclusion pathology, whereas all persons w/ <i>GRN</i> -FTD show ub-ir neuronal intranuclear inclusions. ²	Presenile dementia affecting frontal & temporal cortex & some subcortical nuclei. Variable presentation; may present w/slowly progressive behavioral changes, language disturbances, &/or extrapyramidal signs; progresses over a few yrs to profound dementia w/ mutism. 25%-40% of families w/AD FTD have mutation of <i>MAPT</i> .
Less commonly involved genes					
<i>CHMP2B</i>	CHMP2B-FTD	Typically in late 50s		Neuropathology assoc w/ ubiquitin-positive but TDP-43- & FUS-negative inclusions	Usually presents w/a frontal lobe syndrome, parkinsonism, dystonia, pyramidal signs. Myoclonus may occur later in disease course.
<i>TARDBP</i>	TARDBP-related ALS or ALS w/FTD	41-60 yrs	2-4 yrs	TDP-43 inclusions in upper & lower motor neurons & cortex	Assoc w/~3% of familial ALS & occasionally FTD w/ALS
<i>VCP</i>	Inclusion body myopathy w/Paget disease of bone & FTD (IBMPFD)	Muscle disease & PDB: age 42 yrs; FTD: age 55 yrs		Numerous intranuclear & infrequent # of neuronal cytoplasmic inclusions & dystrophic neuritis seen in neuropathology	Adult-onset proximal & distal muscle weakness (clinically LGMD ³), early-onset PDB ⁴ , & FTD. Early-stage FTD: dysnomia, dyscalculia, comprehension deficits, paraphasic errors, & relative preservation of memory. Later stages: inability to speak, auditory comprehension deficits for even 1-step commands, alexia, & agraphia

AD= autosomal dominant; ALS = amyotrophic lateral sclerosis; DiffDx = differential diagnosis; FTD = frontotemporal dementia; bvFTD = behavioral variant FTD; FTDP = frontotemporal dementia with parkinsonism; FUS = fused in sarcoma; LGMD = limb-girdle muscular dystrophy; PNFA = progressive nonfluent aphasia; PDB = Paget disease of bone; PPA = primary progressive aphasia

1. See [Amyotrophic Lateral Sclerosis Overview](#).

2. Ghetti et al [2003], Mackenzie [2007]

3. Muscle weakness progresses to involve other limb & respiratory muscles; cardiac failure & cardiomyopathy have been observed in later stages of IBMPFD.

4. Paget disease of bone (PDB) involves focal areas of increased bone turnover that typically lead to spine and/or hip pain and localized enlargement and deformity of the long bones.

Management

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with *GRN* frontotemporal dementia (*GRN*-FTD), the following evaluations (if not performed as part of the evaluation that led to the diagnosis) are recommended:

- Detailed general, neurologic, and family history
- Physical examination
- Neurologic examination
- Cognitive examination. When clinical cognitive assessments are not informative enough, a neuropsychological assessment may be performed to provide a more comprehensive and objective view of a patient's cognitive function. Formal neuropsychological assessment requires comparison of the patient's raw score on a specific test to a large general population normative sample which is usually drawn from a population comparable to that of the person being examined. This allows for the patient's performance to be compared to a suitable control group, adjusted for age, sex, level of education, and/or ethnicity. While much more sensitive than bedside clinical cognitive examination, such assessment is resource intensive and time consuming.
- Discussion of capabilities for job and for driving
- Discussion of advanced care planning
- Consultation with a clinical geneticist and/or genetic counselor

Treatment of Manifestations

There is currently no known treatment for *GRN*-FTD or FTD in general. Psychosocial support is essential in the management of FTD and should include occupational therapy and environmental and physical interventions.

However, some behavioral manifestations such as apathy, impulsivity, and compulsiveness may respond to selective serotonin reuptake inhibitors. Behavioral changes and the loss of insight and judgment in individuals with *GRN*-FTD often present a considerable burden for caregivers. Information about the disease and psychological support for partners or other caregivers is essential. Caregiver support groups are valuable.

The behavioral and psychological manifestations should be treated as in other types of FTD. There is no consensus treatment guideline for *GRN*-FTD. In clinical practice those affected individuals who have very aggressive behavior have proven quite difficult to treat and have in some instances been treated with high doses of antipsychotics and/or antidepressants in order to relieve the physical aggressiveness. Administered antipsychotics should be reevaluated at short intervals with the purpose of discontinuation as soon as feasible.

Roaming, delusions, and hallucinations may respond to antipsychotic medications.

Although reports have suggested potential benefits with certain pharmacotherapy on management of FTD in general, evidence from randomized controlled trials is limited [Freedman 2007]. All of the following findings require confirmation with larger clinical trials:

- One double-blind placebo-controlled crossover trial suggests that trazodone, a serotonergic agent, may be beneficial in treating the symptoms of irritability, agitation, depression, and eating disorders in FTD [Lebert et al 2004].
- While an open-label study suggested some benefits on behavioral symptoms with paroxetine, a double-blind placebo-controlled trial of ten subjects found worsening of performance on paired associates learning, reversal learning, and delayed pattern recognition [Moretti et al 2003, Deakin et al 2004].

- A study of galantamine in bvFTD and primary progressive aphasia (PPA) found significant benefits in subjects with PPA but not in those with bvFTD [Kertesz et al 2005]. A follow-up study of 36 individuals who were on galantamine therapy for 18 weeks revealed stabilization but not improvement on language scores in the PPA group [Kertesz et al 2008].
- A 12-month open-label rivastigmine trial showed improvement of behavioral symptoms and decreased caregiver burden in individuals with FTD; however, the treatment did not prevent cognitive decline [Moretti et al 2004].
- A double-blind placebo-controlled crossover study of methylphenidate found attenuation of risk-taking behavior but worsening of spatial span [Rahman et al 2006].
- A small clinical trial of dextroamphetamine treatment on eight individuals with bvFTD revealed improvement of behavioral symptoms [Huey et al 2008].
- A few open-label studies of memantine, a partial NMDA agonist, demonstrated an improvement on the frontal battery inventory in individuals with bvFTD after a six-month trial, but a decline in other cognitive performance [Diehl-Schmid et al 2008]. Among the three subtypes of FTD, PPA-PNFA remained stable on cognitive and functional measurements when treated with memantine [Boxer et al 2009]. A study using [¹⁸F]-fluorodeoxyglucose positron emission tomography (FDG-PET) as a surrogate outcome in individuals with semantic dementia found that cortical metabolic activity in salience network hubs was sustained when treated with memantine over a six-month period [Chow et al 2013]. While a meta-analysis suggest some benefit with memantine, the sample sizes were small and further studies with larger samples sizes are needed [Kishi et al 2015].

Note: Donepezil treatment has been associated with exacerbation of disinhibition and compulsion symptoms [Mendez et al 2007].

Surveillance

Patients are often followed in a memory disorder clinic or a similar multidisciplinary clinic involving neurologic and psychiatric services and follow-up medical care.

Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

Search [ClinicalTrials.gov](https://clinicaltrials.gov) in the US and [EU Clinical Trials Register](https://clinicaltrialsregister.eu) in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

GRN frontotemporal dementia (GRN-FTD) is inherited in an autosomal dominant manner.

Risk to Family Members

Parents of a proband

- Most (95%) individuals diagnosed with *GRN*-FTD have an affected parent [Gass et al 2006].
- A proband with *GRN*-FTD may have the disorder as the result of a *de novo GRN* pathogenic variant. The proportion of cases caused by a *de novo* pathogenic variant is unknown but is estimated at 5% or fewer.
- Recommendations for the evaluation of parents of a proband with an apparent *de novo GRN* pathogenic variant include a neurologic assessment and molecular genetic testing for the *GRN* variant identified in the proband.
- If the *GRN* pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, possible explanations include a *de novo GRN* pathogenic variant in the proband or germline mosaicism in a parent.* Though theoretically possible, no instances of a proband inheriting a pathogenic variant from a parent with germline mosaicism have been reported.
* Misattributed parentage can also be explored as an alternative explanation for an apparent *de novo* pathogenic variant.
- The family history of some individuals diagnosed with *GRN*-FTD may appear to be negative because of a milder phenotypic presentation, early death of the parent before the onset of manifestations, or age-related/reduced penetrance. Therefore, an apparently negative family history cannot be confirmed unless molecular genetic testing for the *GRN* variant identified in the proband has been performed on the parents of the proband.

Sibs of a proband. The risk to the sibs of the proband depends on the clinical/genetic status of the proband's parents:

- If a parent of the proband is affected and/or is known to have the *GRN* pathogenic variant identified in the proband, the risk to the sibs is 50%. Intrafamilial variability in clinical presentation and age of onset is observed in *GRN*-FTD.
- If the pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is estimated to be 1% because of the theoretic possibility of parental germline mosaicism [Rahbari et al 2016].
- If the clinically unaffected parents have not been tested for the *GRN* pathogenic variant identified in the proband, sibs are still presumed to be at increased risk for *GRN*-FTD because of the possibility of age-related/reduced penetrance in a parent heterozygous for the *GRN* pathogenic variant or the theoretic possibility of parental germline mosaicism.

Offspring of a proband. Each child of an individual with *GRN*-FTD has a 50% chance of inheriting the *GRN* pathogenic variant.

Other family members. The risk to other family members depends on the status of the proband's parents: if a parent has the *GRN* pathogenic variant identified in the proband, the parent's family members may also be at risk.

Related Genetic Counseling Issues

Predictive testing (i.e., testing of asymptomatic at-risk individuals)

- Predictive testing for at-risk relatives is possible once the *GRN* pathogenic variant has been identified in an affected family member.

- Potential consequences of such testing (including but not limited to socioeconomic changes and the need for long-term follow up and evaluation arrangements for individuals with a positive test result) as well as the capabilities and limitations of predictive testing should be discussed in the context of formal genetic counseling prior to testing.

Predictive testing in minors (i.e., testing of asymptomatic at-risk individuals younger than age 18 years)

- For asymptomatic minors at risk for adult-onset conditions for which early treatment would have no beneficial effect on disease morbidity and mortality, predictive genetic testing is considered inappropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.
- For more information, see the National Society of Genetic Counselors [position statement](#) on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics [policy statement](#): ethical and policy issues in genetic testing and screening of children.

In a family with an established diagnosis of GRN-FTD, it is appropriate to consider testing of symptomatic individuals regardless of age.

Family planning

- The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
- It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk of being affected.

Prenatal Testing and Preimplantation Genetic Testing

Once the GRN pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing for GRN-FTD are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.

Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click [here](#).

- **Association for Frontotemporal Degeneration (AFTD)**
Phone: 866-507-7222
Email: info@theaftd.org
www.theaftd.org
- **FTD Talk**
United Kingdom
Email: j.rohrer@ucl.ac.uk
www.ftdtalk.org
- **National Institute of Neurological Disorders and Stroke (NINDS)**

PO Box 5801
 Bethesda MD 20824
Phone: 800-352-9424 (toll-free); 301-496-5751; 301-468-5981 (TTY)
[Frontotemporal Dementia Information Page](#)

- **Rare Dementia Support**
 United Kingdom
Email: contact@raredementiasupport.org
www.raredementiasupport.org
- **ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration - Registry**
www.allftd.org
- **FTD Disorders Registry**
 FTD Disorders Registry

Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

Table A. GRN Frontotemporal Dementia: Genes and Databases

Gene	Chromosome Locus	Protein	Locus-Specific Databases	HGMD	ClinVar
GRN	17q21.31	Progranulin	Neuronal Ceroid Lipofuscinoses; NCL Mutations (GRN) GRN database	GRN	GRN

Data are compiled from the following standard references: gene from [HGNC](#); chromosome locus from [OMIM](#); protein from [UniProt](#). For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click [here](#).

Table B. OMIM Entries for GRN Frontotemporal Dementia ([View All in OMIM](#))

138945	GRANULIN PRECURSOR; GRN
607485	FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, GRN-RELATED

Molecular Pathogenesis

The granulins are a family of cysteine-rich polypeptides, some of which have growth-modulating activity. All four known human granulin-like peptides are produced from a single precursor, progranulin. *GRN* encodes progranulin, a glycoprotein with a highly conserved 12-cysteine backbone consensus sequence that is repeated seven times [Bateman & Bennett 1998, Cruts et al 2006]. Each tandem granulin repeat is encoded by two nonequivalent exons, a configuration unique to the granulins that would permit the formation of hybrid granulin-like proteins by alternate splicing.

Progranulin, also known as PC-cell-derived growth factor, proepithelin, granulin-epithelin, or acrogranin, is a high-molecular-weight secreted mitogen. Progranulin mRNA is widely expressed in rapidly cycling epithelial cells, in the immune system, and in neurons such as cerebellar Purkinje cells, suggesting an important function in these tissues. Progranulin is involved in multiple physiologic processes such as cellular proliferation and survival as well as tissue repair, and pathologic processes including tumorigenesis [He & Bateman 2003].

Full-length progranulin has trophic and anti-inflammatory activity, while the cleaved granulin peptides promote inflammatory activity. In the periphery, progranulin is involved in wound healing responses and modulates

inflammatory events. In the central nervous system, progranulin is expressed by neurons and microglia [Eriksen & Mackenzie 2008].

There is growing evidence that *GRN* is involved in lysosomal function, and impairment in lysosomal trafficking and lysosomal glucocerebrosidase activities may exacerbate the pathology of frontotemporal lobar degeneration [Tanaka et al 2014, Zhou et al 2017, Zhou et al 2019, Valdez et al 2020]. There is also evidence that progranulin and granulin peptides have trophic and neuroprotective effects [Townley et al 2018].

Mechanism of disease causation. *GRN*-FTD occurs through a loss-of-function mechanism as evidenced by the majority of pathogenic variants being nonsense, frameshift, and splice-site variants [Baker et al 2006, Cruts et al 2006, Gass et al 2006, van der Zee et al 2007].

Deletion of the progranulin locus can also lead to the same clinical presentation of *GRN*-FTD as a result of haploinsufficiency [Gijssels et al 2008].

Table 3. Notable *GRN* Pathogenic Variants

Reference Sequences	DNA Nucleotide Change (Alias ¹)	Predicted Protein Change	Comment [Reference]
NM_002087 NP_002078	c.1477C>T (g.3240C>T)	p.Arg493Ter	<ul style="list-style-type: none"> Most frequently found pathogenic variant 60% of individuals w/this variant were affected by age 60 yrs; >95% by age 70 yrs [Rademakers et al 2007]. Haplotype analyses suggest a founder effect [Gass et al 2006, Bronner et al 2007, van der Zee et al 2007].
	c.26C>A	p.Ala9Asp	<ul style="list-style-type: none"> 2nd most commonly reported pathogenic variant Only 25% reported to have a family history, suggesting possible ↓ penetrance or <i>de novo</i> occurrence [Chen-Plotkin et al 2011].
NM_002087	c.-8+5G>C (IVS0+5G>C)	--	Founder variant in an extended Belgian pedigree [Cruts et al 2006]

Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen.hgvs.org). See [Quick Reference](#) for an explanation of nomenclature.

1. Variant designation that does not conform to current naming conventions

Chapter Notes

Acknowledgments

The authors gratefully acknowledge the funding received from the Canadian Institutes of Health Research operating grant #74580 and #179009 in support of their research on FTD as well as the collaborations of the investigators of the UBC FTD research team including Drs I Mackenzie, B Hallam, C Jacova, E Dwosh, and AD Sadovnick. Dr GYR Hsiung is supported by a CIHR Clinical Genetics Investigatorship.

Revision History

- 6 February 2020 (bp) Comprehensive update posted live
- 14 March 2013 (me) Comprehensive update posted live
- 7 September 2007 (me) Review posted live
- 1 June 2007 (gyrh) Original submission

References

Literature Cited

- Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Biochem Biophys Res Commun*. 2006;351:602–11. PubMed PMID: 17084815.
- Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. *Neurology*. 2013;80:496–503. PubMed PMID: 23359374.
- Ayala YM, Zago P, D'Ambrogio A, Xu YF, Petrucelli L, Buratti E, Baralle FE. Structural determinants of the cellular localization and shuttling of TDP-43. *J Cell Sci*. 2008;121:3778–85. PubMed PMID: 18957508.
- Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature*. 2006;442:916–9. PubMed PMID: 16862116.
- Bateman A, Bennett HP. Granulins: the structure and function of an emerging family of growth factors. *J Endocrinol*. 1998;158:145–51. PubMed PMID: 9771457.
- Beck J, Rohrer JD, Campbell T, Isaacs A, Morrison KE, Goodall EF, Warrington EK, Stevens J, Revesz T, Holton J, Al-Sarraj S, King A, Scahill R, Warren JD, Fox NC, Rossor MN, Collinge J, Mead S. A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. *Brain*. 2008;131:706–20. PubMed PMID: 18234697.
- Behrens MI, Mukherjee O, Tu PH, Liscic RM, Grinberg LT, Carter D, Paulsmeyer K, Taylor-Reinwald L, Gitcho M, Norton JB, Chakraverty S, Goate AM, Morris JC, Cairns NJ. Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation. *Alzheimer Dis Assoc Disord*. 2007;21:1–7. PubMed PMID: 17334266.
- Benussi L, Ghidoni R, Pegoiani E, Moretti DV, Zanetti O, Binetti G. Progranulin Leu271LeufsX10 is one of the most common FTLN and CBS associated mutations worldwide. *Neurobiol Dis*. 2009;33:379–85. PubMed PMID: 19101631.
- Bird T, Knopman D, VanSwieten J, Rosso S, Feldman H, Tanabe H, Graff-Raford N, Geschwind D, Verpillat P, Hutton M. Epidemiology and genetics of frontotemporal dementia/Pick's disease. *Ann Neurol*. 2003;54 Suppl 5:S29–31. PubMed PMID: 12833366.
- Boxer AL, Lipton AM, Womack K, Merrilees J, Neuhaus J, Pavlic D, Gandhi A, Red D, Martin-Cook K, Svetlik D, Miller BL. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. *Alzheimer Dis Assoc Disord*. 2009;23:211–7. PubMed PMID: 19812461.
- Bronner IF, Rizzu P, Seelaar H, van Mil SE, Anar B, Azmani A, Kaat LD, Rosso S, Heutink P, van Swieten JC. Progranulin mutations in Dutch familial frontotemporal lobar degeneration. *Eur J Hum Genet*. 2007;15:369–74. PubMed PMID: 17228326.
- Bruni AC, Momeni P, Bernardi L, Tomaino C, Frangipane F, Elder J, Kawarai T, Sato C, Pradella S, Wakutani Y, Anfossi M, Gallo M, Geracitano S, Costanzo A, Smirne N, Curcio SA, Mirabelli M, Puccio G, Colao R, Maletta RG, Kertesz A, St George-Hyslop P, Hardy J, Rogaeva E. Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation. *Neurology*. 2007;69:140–7. PubMed PMID: 17620546.
- Carecchio M, Fenoglio C, De Riz M, Guidi I, Comi C, Cortini F, Venturelli E, Restelli I, Cantoni C, Bresolin N, Monaco F, Scarpini E, Galimberti D. Progranulin plasma levels as potential biomarker for the identification

of GRN deletion carriers. A case with atypical onset as clinical amnesic mild cognitive impairment converted to Alzheimer's disease. *J Neurol Sci.* 2009;287:291–3. PubMed PMID: 19683260.

- Caroppo P, Habert MO, Durrleman S, Funkiewiez A, Perlberg V, Hahn V, Bertin H, Gaubert M, Routier A, Hannequin D, Deramecourt V, Pasquier F, Rivaud-Pechoux S, Vercelletto M, Edouart G, Valabregue R, Lejeune P, Didic M, Corvol JC, Benali H, Lehericy S, Dubois B, Colliot O, Brice A, Le Ber I, et al. Lateral temporal lobe: an early imaging marker of the presymptomatic GRN disease? *J Alzheimers Dis.* 2015;47:751–9. PubMed PMID: 26401709.
- Caso F, Villa C, Fenoglio C, Santangelo R, Agosta F, Coppi E, Falautano M, Comi G, Filippi M, Scarpini E, Magnani G, Galimberti D. The progranulin (GRN) Cys157LysfsX97 mutation is associated with nonfluent variant of primary progressive aphasia clinical phenotype. *J Alzheimers Dis.* 2012;28:759–63. PubMed PMID: 22072213.
- Chen-Plotkin AS, Martinez-Lage M, Sleiman PM, Hu W, Greene R, Wood EM, Bing S, Grossman M, Schellenberg GD, Hatanpaa KJ, Weiner MF, White CL 3rd, Brooks WS, Halliday GM, Kril JJ, Gearing M, Beach TG, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Pickering-Brown SM, Snowden J, van Swieten JC, Heutink P, Seelaar H, Murrell JR, Ghetti B, Spina S, Grafman J, Kaye JA, Woltjer RL, Mesulam M, Bigio E, Lladó A, Miller BL, Alzualde A, Moreno F, Rohrer JD, Mackenzie IR, Feldman HH, Hamilton RL, Cruts M, Engelborghs S, De Deyn PP, Van Broeckhoven C, Bird TD, Cairns NJ, Goate A, Frosch MP, Riederer PF, Bogdanovic N, Lee VM, Trojanowski JQ, Van Deerlin VM. Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. *Arch Neurol.* 2011;68:488–97. PubMed PMID: 21482928.
- Chow TW, Fam D, Graff-Guerrero A, Verhoeff NP, Tang-Wai DF, Masellis M, Black SE, Wilson AA, Houle S, Pollock BG. Fluorodeoxyglucose positron emission tomography in semantic dementia after 6 months of memantine: an open-label pilot study. *Int J Geriatr Psychiatry.* 2013;28:319–25. PubMed PMID: 22674572.
- Clot F, Rovelet-Lecrux A, Lamari F, Noël S, Keren B, Camuzat A, Michon A, Jornea L, Laudier B, de Septenville A, Caroppo P, Champion D, Cazeneuve C, Brice A, LeGuern E, Le Ber I, et al. Partial deletions of the GRN gene are a cause of frontotemporal lobar degeneration. *Neurogenetics.* 2014;15:95–100. PubMed PMID: 24469240.
- Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, van Duijn C, Peeters K, Sciot R, Santens P, De Pooter T, Mattheijssens M, Van den Broeck M, Cuijt I, Vennekens K, De Deyn PP, Kumar-Singh S, Van Broeckhoven C. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. *Nature.* 2006;442:920–4. PubMed PMID: 16862115.
- Davion S, Johnson N, Weintraub S, Mesulam MM, Engberg A, Mishra M, Baker M, Adamson J, Hutton M, Rademakers R, Bigio EH. Clinicopathologic correlation in PGRN mutations. *Neurology.* 2007;69:1113–21. PubMed PMID: 17522386.
- Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. *Psychopharmacology (Berl).* 2004;172:400–8. PubMed PMID: 14666399.
- Diehl-Schmid J, Forstl H, Perneczky R, Pohl C, Kurz A. A 6-month, open-label study of memantine in patients with frontotemporal dementia. *Int J Geriatr Psychiatry.* 2008;23:754–9. PubMed PMID: 18213609.
- Eriksen JL, Mackenzie IR. Progranulin: normal function and role in neurodegeneration. *J Neurochem.* 2008;104:287–97. PubMed PMID: 17953663.
- Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, Bisceglia G, Rovelet-Lecrux A, Boeve B, Petersen RC, Dickson DW, Younkin SG, Deramecourt V, Crook J, Graff-Radford NR, Rademakers R. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. *Brain.* 2009;132:583–91. PubMed PMID: 19158106.

- Freedman M. Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches. *Can J Neurol Sci.* 2007;34 Suppl 1:S118–24. PubMed PMID: 17469694.
- Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J, Crook R, Melquist S, Kuntz K, Petersen R, Josephs K, Pickering-Brown SM, Graff-Radford N, Uitti R, Dickson D, Wszolek Z, Gonzalez J, Beach TG, Bigio E, Johnson N, Weintraub S, Mesulam M, White CL 3rd, Woodruff B, Caselli R, Hsiung GY, Feldman H, Knopman D, Hutton M, Rademakers R. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. *Hum Mol Genet.* 2006;15:2988–3001. PubMed PMID: 16950801.
- Ghetti B, Hutton M, Wszolek Z. Frontotemporal dementia and parkinsonism linked to chromosome 17 associated with Tau gene mutations (FTDP-17T). In: Dickson DW, ed. *Neurodegeneration: the Molecular Pathology of Dementia and Movement Disorders*. Basel, Switzerland: ISN Neuropath Press; 2003:86–102.
- Gijssels I, van der Zee J, Engelborghs S, Goossens D, Peeters K, Mattheijssens M, Corsmit E, Del-Favero J, De Deyn PP, Van Broeckhoven C, Cruts M. Progranulin locus deletion in frontotemporal dementia. *Hum Mutat.* 2008;29:53–8. PubMed PMID: 18157829.
- Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M. Classification of primary progressive aphasia and its variants. *Neurology.* 2011;76:1006–14. PubMed PMID: 21325651.
- He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. *J Mol Med.* 2003;81:600–12. PubMed PMID: 12928786.
- Huey ED, Garcia C, Wassermann EM, Tierney MC, Grafman J. Stimulant treatment of frontotemporal dementia in 8 patients. *J Clin Psychiatry.* 2008;69:1981–2. PubMed PMID: 19203481.
- Huey ED, Grafman J, Wassermann EM, Pietrini P, Tierney MC, Ghetti B, Spina S, Baker M, Hutton M, Elder JW, Berger SL, Heflin KA, Hardy J, Momeni P. Characteristics of frontotemporal dementia patients with a progranulin mutation. *Ann Neurol.* 2006;60:374–80. PubMed PMID: 16983677.
- Jacova C, Hsiung GY, Tawankanjanachot I, Dinelle K, McCormick S, Gonzalez M, et al. Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. *Neurology.* 2013;81:1322–31. PubMed PMID: 24005336.
- Josephs KA, Ahmed Z, Katsuse O, Parisi JF, Boeve BF, Knopman DS, Petersen RC, Davies P, Duara R, Graff-Radford NR, Uitti RJ, Rademakers R, Adamson J, Baker M, Hutton ML, Dickson DW. Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. *J Neuropathol Exp Neurol.* 2007;66:142–51. PubMed PMID: 17278999.
- Kamate M, Detroja M, Hattiholi V. Neuronal ceroid lipofuscinosis type-11 in an adolescent. *Brain Dev.* 2019;41:542–5. PubMed PMID: 30922528.
- Kelley BJ, Haidar W, Boeve BF, Baker M, Shiung M, Knopman DS, Rademakers R, Hutton M, Adamson J, Kuntz KM, Dickson DW, Parisi JE, Smith GE, Petersen RC. Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. *Arch Neurol.* 2010;67:171–7. PubMed PMID: 20142525.
- Kertesz A, Blair M, Davidson W, Light M, Morlog D, Brashear R. A Pilot study of the safety and efficacy of galantamine for Pick complex/frontotemporal dementia (FTD). *Ann Neurol.* 2005;58:S47.
- Kertesz A, Morlog D, Light M, Blair M, Davidson W, Jesso S, Brashear R. Galantamine in frontotemporal dementia and primary progressive aphasia. *Dement Geriatr Cogn Disord.* 2008;25:178–85. PubMed PMID: 18196898.
- Kishi T, Matsunaga S, Iwata N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. *Neuropsychiatr Dis Treat.* 2015;11:2883–5. PubMed PMID: 26648724.
- Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj E, Rovelet-Lecrux A, Hahn-Barma V, van der Zee J, Clot F, Bakchine S, Puel M, Ghanim M, Lacomblez L, Mikol J, Deramecourt V, Lejeune P, de la Sayette V, Belliard

- S, Vercelletto M, Meyrignac C, Van Broeckhoven C, Lambert JC, Verpillat P, Campion D, Habert MO, Dubois B, Brice A. French research network on FTD/FTD-MND. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. *Brain*. 2008;131:732–46. PubMed PMID: 18245784.
- Le Ber I, van der Zee J, Hannequin D, Gijselinck I, Campion D, Puel M, Laquerriere A, De Pooter T, Camuzat A, Van den Broeck M, Dubois B, Sellal F, Lacomblez L, Vercelletto M, Thomas-Anterion C, Michel BF, Golfier V, Didic M, Salachas F, Duyckaerts C, Cruts M, Verpillat P, Van Broeckhoven C, Brice A. Progranulin null mutations in both sporadic and familial frontotemporal dementia. *Hum Mutat*. 2007;28:846–55. PubMed PMID: 17436289.
- Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. *Dement Geriatr Cogn Disord*. 2004;17:355–9. PubMed PMID: 15178953.
- Mackenzie IR. The neuropathology and clinical phenotype of FTD with progranulin mutations. *Acta Neuropathol (Berl)*. 2007;114:49–54. PubMed PMID: 17458552.
- Mackenzie IR, Baker M, Pickering-Brown S, Hsiung GY, Lindholm C, Dwosh E, Gass J, Cannon A, Rademakers R, Hutton M, Feldman HH. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. *Brain*. 2006;129:3081–90. PubMed PMID: 17071926.
- Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann DM, Lee VM. A harmonized classification system for FTLD-TDP pathology. *Acta Neuropathol*. 2011;122:111–3. PubMed PMID: 21644037.
- Masellis M, Momeni P, Meschino W, Heffner R Jr, Elder J, Sato C, Liang Y, St George-Hyslop P, Hardy J, Bilbao J, Black S, Rogaeva E. Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. *Brain*. 2006;129:3115–23. PubMed PMID: 17030534.
- Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. *Am J Geriatr Psychiatry*. 2007;15:84–7. PubMed PMID: 17194818.
- Mesulam M, Johnson N, Krefft TA, Gass JM, Cannon AD, Adamson JL, Bigio EH, Weintraub S, Dickson DW, Hutton ML, Graff-Radford NR. Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families. *Arch Neurol*. 2007;64:43–7. PubMed PMID: 17210807.
- Mesulam MM. Primary progressive aphasia. *Ann Neurol*. 2001;49:425–32. PubMed PMID: 11310619.
- Milan G, Napoletano S, Pappatà S, et al. GRN deletion in familial frontotemporal dementia showing association with clinical variability in 3 familial cases. *Neurobiol Aging*. 2017;53:193.e9–193.e16.
- Moreno F, Indakoetxea B, Barandiaran M, Alzualde A, Gabilondo A, Estanga A, Ruiz J, Ruibal M, Bergareche A, Martí-Massó JF, López de Munain A. "Frontotemporoparietal" dementia: clinical phenotype associated with the c.709-1G>A PGRN mutation. *Neurology*. 2009;73:1367–74. PubMed PMID: 19858458.
- Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. *Drugs Aging*. 2004;21:931–7. PubMed PMID: 15554751.
- Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. *Eur Neurol*. 2003;49:13–9. PubMed PMID: 12464713.
- Mukherjee O, Pastor P, Cairns NJ, Chakraverty S, Kauwe JS, Shears S, Behrens MI, Budde J, Hinrichs AL, Norton J, Levitch D, Taylor-Reinwald L, Gitcho M, Tu PH, Tenenholz Grinberg L, Liscic RM, Armendariz J, Morris JC, Goate AM. HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. *Ann Neurol*. 2006;60:314–22. PubMed PMID: 16983685.

- Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, Forman MS, Troost D, Kretzschmar HA, Trojanowski JQ, Lee VM. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. *Acta Neuropathol.* 2009;117:137–49. PubMed PMID: 19125255.
- Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science.* 2006;314:130–3. PubMed PMID: 17023659.
- Pasquier F, Fukui T, Sarazin M, Pijnenburg Y, Diehl J, Grundman M, Miller BL. Laboratory investigations and treatment in frontotemporal dementia. *Ann Neurol.* 2003;54 Suppl 5:S32–5.
- Pickering-Brown SM, Rollinson S, Du Plessis D, Morrison KE, Varma A, Richardson AM, Neary D, Snowden JS, Mann DM. Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. *Brain.* 2008;131:721–31. PubMed PMID: 18192287.
- Pottier C, Zhou X, Perkerson RB 3rd, Baker M, Jenkins GD, Serie DJ, Ghidoni R, Benussi L, Binetti G, López de Munain A, Zulaica M, Moreno F, Le Ber I, Pasquier F, Hannequin D, Sánchez-Valle R, Antonell A, Lladó A, Parsons TM, Finch NA, Finger EC, Lippa CF, Huey ED, Neumann M, Heutink P, Synofzik M, Wilke C, Rissman RA, Slawek J, Sitek E, Johannsen P, Nielsen JE, Ren Y, van Blitterswijk M, DeJesus-Hernandez M, Christopher E, Murray ME, Bieniek KF, Evers BM, Ferrari C, Rollinson S, Richardson A, Scarpini E, Fumagalli GG, Padovani A, Hardy J, Momeni P, Ferrari R, Frangipane F, Maletta R, Anfossi M, Gallo M, Petrucelli L, Suh E, Lopez OL, Wong TH, van Rooij JGJ, Seelaar H, Mead S, Caselli RJ, Reiman EM, Noel Sabbagh M, Kjolby M, Nykjaer A, Karydas AM, Boxer AL, Grinberg LT, Grafman J, Spina S, Oblak A, Mesulam MM, Weintraub S, Geula C, Hodges JR, Piguet O, Brooks WS, Irwin DJ, Trojanowski JQ, Lee EB, Josephs KA, Parisi JE, Ertekin-Taner N, Knopman DS, Nacmias B, Piaceri I, Bagnoli S, Sorbi S, Gearing M, Glass J, Beach TG, Black SE, Masellis M, Rogaeva E, Vonsattel JP, Honig LS, Kofler J, Bruni AC, Snowden J, Mann D, Pickering-Brown S, Diehl-Schmid J, Winkelmann J, Galimberti D, Graff C, Öijerstedt L, Troakes C, Al-Sarraj S, Cruchaga C, Cairns NJ, Rohrer JD, Halliday GM, Kwok JB, van Swieten JC, White CL 3rd, Ghetti B, Murrell JR, Mackenzie IRA, Hsiung GR, Borroni B, Rossi G, Tagliavini F, Wszolek ZK, Petersen RC, Bigio EH, Grossman M, Van Deerlin VM, Seeley WW, Miller BL, Graff-Radford NR, Boeve BF, Dickson DW, Biernacka JM, Rademakers R. Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. *Lancet Neurol.* 2018;17:548–58. PubMed PMID: 29724592.
- Rademakers R, Baker M, Gass J, Adamson J, Huey ED, Momeni P, Spina S, Coppola G, Karydas AM, Stewart H, Johnson N, Hsiung GY, Kelley B, Kuntz K, Steinbart E, Wood EM, Yu CE, Josephs K, Sorenson E, Womack KB, Weintraub S, Pickering-Brown SM, Schofield PR, Brooks WS, Van Deerlin VM, Snowden J, Clark CM, Kertesz A, Boylan K, Ghetti B, Neary D, Schellenberg GD, Beach TG, Mesulam M, Mann D, Grafman J, Mackenzie IR, Feldman H, Bird T, Petersen R, Knopman D, Boeve B, Geschwind DH, Miller B, Wszolek Z, Lippa C, Bigio EH, Dickson D, Graff-Radford N, Hutton M. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. *Lancet Neurol.* 2007;6:857–68. PubMed PMID: 17826340.
- Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al. Timing, rates and spectra of human germline mutation. *Nat Genet.* 2016;48:126–33. PubMed PMID: 26656846.
- Rahman S, Robbins TW, Hodges JR, Mehta MA, Nestor PJ, Clark L, Sahakian BJ. Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. *Neuropsychopharmacology.* 2006;31:651–8. PubMed PMID: 16160709.
- Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-

- Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain*. 2011;134:2456–77. PubMed PMID: 21810890.
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17:405–24. PubMed PMID: 25741868.
- Rohrer JD, Beck J, Plagnol V, Gordon E, Lashley T, Revesz T, Janssen JC, Fox NC, Warren JD, Rossor MN, Mead S, Schott JM. Exome sequencing reveals a novel partial deletion in the progranulin gene causing primary progressive aphasia. *J Neurol Neurosurg Psychiatry*. 2013;84:1411–2. PubMed PMID: 23904625.
- Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. *Curr Opin Neurol*. 2011;24:542–9. PubMed PMID: 21986680.
- Rovelet-Lecrux A, Deramecourt V, Legallic S, Maurage CA, Le Ber I, Brice A, Lambert JC, Frébourg T, Hannequin D, Pasquier F, Campion D. Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. *Neurobiol Dis*. 2008;31:41–5. PubMed PMID: 18479928.
- Schymick JC, Yang Y, Andersen PM, Vonsattel JP, Greenway M, Momeni P, Elder J, Chio A, Restagno G, Robberecht W, Dahlberg C, Mukherjee O, Goate A, Graff-Radford N, Caselli RJ, Hutton M, Gass J, Cannon A, Rademakers R, Singleton AB, Hardiman O, Rothstein J, Hardy J, Traynor BJ. Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. *J Neurol Neurosurg Psychiatry*. 2007;78:754–6. PubMed PMID: 17371905.
- Seeley WW, Bauer AM, Miller BL, Gorno-Tempini ML, Kramer JH, Weiner M, Rosen HJ. The natural history of temporal variant frontotemporal dementia. *Neurology*. 2005;64:1384–90. PubMed PMID: 15851728.
- Sendtner M. TDP-43: multiple targets, multiple disease mechanisms? *Nat Neurosci*. 2011;14:403–5. PubMed PMID: 21445063.
- Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. *Am J Hum Genet*. 2012;90:1102–7. PubMed PMID: 22608501.
- Spina S, Murrell JR, Huey ED, Wassermann EM, Pietrini P, Baraibar MA, Barbeito AG, Troncoso JC, Vidal R, Ghetti B, Grafman J. Clinicopathologic features of frontotemporal dementia with progranulin sequence variation. *Neurology*. 2007;68:820–7. PubMed PMID: 17202431.
- Tanaka Y, Chambers JK, Matsuwaki T, Yamanouchi K, Nishihara M. Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. *Acta neuropathologica communications*. 2014;2:78. PubMed PMID: 25022663.
- Townley RA, Boeve BF, Benarroch EE. Progranulin: functions and neurologic correlations. *Neurology*. 2018;90:118–25. PubMed PMID: 29263224.
- Valdez C, Ysselstein D, Young TJ, Zheng J, Krainc D. Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity. *Hum Mol Genet*. 2020;29:716–26. PubMed PMID: 31600775.
- van der Zee J, Le Ber I, Maurer-Stroh S, Engelborghs S, Gijssels I, Camuzat A, Brouwers N, Vandenberghe R, Sleegers K, Hannequin D, Dermaut B, Schymkowitz J, Campion D, Santens P, Martin JJ, Lacomblez L, De Pooter T, Peeters K, Mattheijssens M, Vercelletto M, Van den Broeck M, Cruts M, De Deyn PP, Rousseau F, Brice A, Van Broeckhoven C. Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. *Hum Mutat*. 2007;28:416.

- Van Langenhove T, van der Zee J, Gijselinck I, Engelborghs S, Vandenberghe R, Vandebulcke M, De Bleecker J, Sieben A, Versijpt J, Ivanoiu A, Deryck O, Willems C, Dillen L, Philtjens S, Maes G, Bäumer V, Van Den Broeck M, Mattheijssens M, Peeters K, Martin JJ, Michotte A, Santens P, De Jonghe P, Cras P, De Deyn PP, Cruts M, Van Broeckhoven C. Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort. *JAMA Neurol.* 2013;70:365–73. PubMed PMID: 23338682.
- Whitwell JL, Jack CR Jr, Baker M, Rademakers R, Adamson J, Boeve BF, Knopman DS, Parisi JF, Petersen RC, Dickson DW, Hutton ML, Josephs KA. Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations. *Arch Neurol.* 2007;64:371–6. PubMed PMID: 17353379.
- Whitwell JL, Weigand SD, Gunter JL, Boeve BF, Rademakers R, Baker M, Knopman DS, Wszolek ZK, Petersen RC, Jack CR Jr, Josephs KA. Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN. *Neurology.* 2011;77:393–8. PubMed PMID: 21753165.
- Zhou X, Paushter DH, Pagan MD, Kim D, Nunez Santos M, Lieberman RL, Overkleeft HS, Sun Y, Smolka MB, Hu F. Progranulin deficiency leads to reduced glucocerebrosidase activity. *PLoS One.* 2019;14:e0212382. PubMed PMID: 31291241.
- Zhou X, Sun L, Bracko O, Choi JW, Jia Y, Nana AL, Brady OA, Hernandez JCC, Nishimura N, Seeley WW, Hu F. Impaired prosaposin lysosomal trafficking in frontotemporal lobar degeneration due to progranulin mutations. *Nat Commun.* 2017;8:15277. PubMed PMID: 28541286.

License

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<http://www.genereviews.org/>) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the [GeneReviews® Copyright Notice and Usage Disclaimer](#). No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the [GeneReviews® Copyright Notice and Usage Disclaimer](#).

For questions regarding permissions or whether a specified use is allowed, contact: admasst@uw.edu.